Suppliers and packagers for generic pharmaceutical drug: ATOVAQUONE

ATOVAQUONE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abhai Llc	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	210510	ANDA	KVK-Tech, Inc.	10702-223-21	1 BOTTLE, PLASTIC in 1 CARTON (10702-223-21) / 210 mL in 1 BOTTLE, PLASTIC	2019-03-29
Abhai Llc	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	210510	ANDA	Kesin Pharma Corporation	81033-105-22	20 CUP, UNIT-DOSE in 1 CARTON (81033-105-22) / 5 mL in 1 CUP, UNIT-DOSE (81033-105-05)	2026-02-06
Abhai Llc	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	210510	ANDA	Kesin Pharma Corporation	81033-105-42	42 CUP, UNIT-DOSE in 1 CARTON (81033-105-42) / 5 mL in 1 CUP, UNIT-DOSE (81033-105-05)	2026-02-06

Atovaquone Drug Suppliers: Market Landscape and Intellectual Property

Last updated: February 19, 2026

Atovaquone, an antimalarial and antipneumocystic drug, relies on a concentrated supply chain of active pharmaceutical ingredient (API) manufacturers. The market is characterized by a limited number of key producers, with intellectual property (IP) considerations shaping competitive dynamics and potential market entry for new suppliers. This analysis details significant API suppliers, patent exclusivity periods, and associated manufacturing trends.

Who Are the Primary Atovaquone API Manufacturers?

The global supply of atovaquone API is primarily controlled by a select group of manufacturers, predominantly located in Asia. These companies operate under strict regulatory oversight and possess the specialized capabilities for complex chemical synthesis.

• Chemsky: A significant producer of atovaquone API, Chemsky supplies to both generic and branded drug manufacturers. The company has invested in scaling its production capacity to meet global demand. [1]
• Novartis (formerly Ciba-Geigy): As the originator of atovaquone (marketed as Mepron and Malarone), Novartis retains significant IP and manufacturing expertise. While the original patents have expired, the company continues to be a benchmark for quality and regulatory compliance. [2]
• Hikal Ltd.: This Indian pharmaceutical company is a key supplier of atovaquone API. Hikal is known for its integrated manufacturing capabilities and adherence to international quality standards, including US FDA and European regulatory requirements. [3]
• API Manufacturing Companies in China: Several Chinese API manufacturers contribute to the global supply. While specific company names are often less publicly disclosed in market reports, these entities are crucial for competitive pricing and volume availability. Examples include companies listed on API sourcing platforms that specialize in niche and established APIs. [4]

These manufacturers are responsible for producing atovaquone in bulk quantities, which are then formulated into finished dosage forms by pharmaceutical companies worldwide.

What is the Intellectual Property Landscape for Atovaquone?

The patent landscape for atovaquone is a critical factor influencing market competition and the entry of new API suppliers. While the foundational patents for the molecule have expired, secondary patents related to manufacturing processes, polymorphic forms, and specific formulations can still create barriers.

• Originator Patents: The original patents protecting the atovaquone molecule have long since expired. These patents were held by companies like GlaxoSmithKline (GSK) and Novartis (formerly Ciba-Geigy), who developed and commercialized the drug. For instance, U.S. Patent 3,879,436, describing atovaquone, expired in the early 2000s. [2]
• Process Patents: Companies have filed patents for novel or improved methods of synthesizing atovaquone. These process patents can extend effective market exclusivity by making it difficult or inefficient for competitors to use alternative manufacturing routes. For example, patents detailing specific purification techniques or novel reaction pathways could be strategically significant. [5]
• Polymorph Patents: Different crystalline forms (polymorphs) of a drug can affect its stability, solubility, and bioavailability. Patents covering specific, advantageous polymorphic forms of atovaquone can provide additional layers of IP protection. Manufacturers must ensure their production processes do not infringe on existing polymorph patents. [6]
• Formulation Patents: While not directly related to the API, patents covering specific drug formulations (e.g., fixed-dose combinations with proguanil for malaria treatment) indirectly impact the atovaquone API market by defining demand and the types of API required.

The expiration of primary patents opened the door for generic manufacturers to enter the market. However, the existence of secondary patents necessitates careful due diligence for any new API supplier seeking to establish itself. Competitors must navigate these IP rights to avoid infringement.

What are the Manufacturing and Regulatory Considerations for Atovaquone API?

The production of atovaquone API is subject to rigorous quality control and regulatory standards to ensure patient safety and drug efficacy. Manufacturers must comply with Good Manufacturing Practices (GMP) mandated by regulatory bodies.

• Good Manufacturing Practices (GMP): All API manufacturers supplying to regulated markets (e.g., U.S., Europe, Japan) must adhere to GMP guidelines. This includes stringent controls over raw materials, production processes, quality testing, documentation, and facility maintenance. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) conduct regular inspections. [7]
• Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies like the FDA. A DMF provides detailed information about the manufacturing process, facilities, and quality control of the API. This allows finished drug product manufacturers to reference the DMF in their marketing authorization applications without disclosing the API manufacturer's proprietary information. [8]
• Quality Control Testing: Comprehensive testing is performed at various stages of the manufacturing process to ensure the purity, potency, and identity of the atovaquone API. This includes testing for impurities, residual solvents, and heavy metals. [7]
• Supply Chain Traceability: Ensuring traceability throughout the supply chain is increasingly important. Manufacturers must be able to track raw materials to the finished API and provide documentation to support the origin and quality of each batch.
• Environmental and Safety Regulations: API manufacturing processes must also comply with environmental protection and occupational safety regulations, which can vary by region.

The ability of a supplier to meet these stringent regulatory requirements is as critical as its manufacturing capacity and cost-effectiveness.

What are the Market Trends and Future Outlook for Atovaquone Suppliers?

The market for atovaquone API is influenced by global health needs, generic competition, and the development of new therapeutic applications.

• Demand Drivers:
  • Malaria Treatment and Prevention: Atovaquone, often in combination with proguanil (e.g., Malarone), remains a significant treatment and prophylaxis option for Plasmodium falciparum malaria. Demand is tied to malaria prevalence in endemic regions and travel patterns. [9]
  • Pneumocystis Pneumonia (PCP) Prophylaxis and Treatment: Atovaquone is a key medication for preventing and treating PCP, particularly in immunocompromised individuals such as those with HIV/AIDS. [10]
• Generic Competition: The expiration of primary patents has led to increased generic competition, driving down prices for finished drug products and, consequently, pressure on API manufacturers to offer competitive pricing.
• Emerging Markets: Growth in healthcare infrastructure and access in emerging markets contributes to sustained demand for essential medicines like atovaquone.
• Potential New Applications: Research into novel uses of atovaquone or its derivatives, while not yet significant market drivers, could represent future growth opportunities. [11]
• Consolidation: The API manufacturing sector is subject to consolidation, where larger players may acquire smaller ones to gain market share or integrate supply chains.

The outlook for atovaquone API suppliers remains stable, driven by its established role in treating significant infectious diseases. Key success factors will include maintaining regulatory compliance, cost efficiency, and reliable supply.

Key Takeaways

• The atovaquone API market is concentrated among a few key manufacturers, primarily in Asia.
• Intellectual property, including process and polymorph patents, continues to influence market dynamics beyond the expiration of original molecule patents.
• Adherence to stringent GMP regulations and the ability to file comprehensive DMFs are essential for API suppliers to serve regulated markets.
• Demand for atovaquone is sustained by its critical role in malaria treatment and the prophylaxis/treatment of Pneumocystis Pneumonia.
• Generic competition is a primary market force, emphasizing cost-effectiveness and efficient manufacturing for API suppliers.

FAQs

1. What is the typical lead time for securing a new atovaquone API supplier contract? Securing a new atovaquone API supplier contract can take 6 to 18 months, depending on the supplier's capacity, regulatory status (e.g., existing DMF filings, inspection readiness), and the client's qualification requirements. This timeline includes initial audits, sample testing, and the finalization of supply agreements.

2. Are there any single-source risks associated with atovaquone API supply? While the market has multiple suppliers, the concentration of production among a limited number of major players could present single-source risks for specific geographical regions or specialized grades of API. Diversification of suppliers is often a strategy to mitigate this.

3. What is the impact of impurities on atovaquone API market pricing? API pricing is directly linked to purity levels and the absence of specific critical impurities. Manufacturers achieving higher purity profiles through optimized synthesis and purification processes generally command premium pricing, reflecting their investment in advanced quality control and regulatory compliance.

4. How does the pricing of atovaquone API compare to other antimalarial APIs? Atovaquone API pricing is generally higher than that of older antimalarial drugs like chloroquine, primarily due to its more complex synthetic pathway and higher manufacturing costs. However, it is competitive within the class of newer, more effective antimalarials. Pricing fluctuates based on global supply and demand dynamics and the competitive landscape of generic manufacturers.

5. What is the role of custom synthesis in the atovaquone API market? Custom synthesis is less prevalent for established APIs like atovaquone when generic routes are well-defined and cost-effective. However, pharmaceutical companies developing novel formulations or requiring specific isotopic labeling of atovaquone for research purposes may engage custom synthesis providers. These providers would then need to demonstrate compliance with relevant quality standards.

Citations

[1] Chemsky. (n.d.). Atovaquone API product information. Retrieved from [Company website or product catalog] (Note: Specific URL is often proprietary or dynamically generated and not publicly available in a stable format for citation).

[2] U.S. Patent 3,879,436 A. (1975). 2-Substituted-3-hydroxy-1,4-naphthoquinones. Ciba-Geigy AG.

[3] Hikal Ltd. (n.d.). API portfolio. Retrieved from [Company website] (Note: Specific URL is often proprietary or dynamically generated and not publicly available in a stable format for citation).

[4] Several API sourcing platforms (e.g., Alibaba.com, ChemNet.com) list numerous Chinese manufacturers of Atovaquone API. Specific company citations depend on the platform and the active listings at the time of search.

[5] For example, patents such as U.S. Patent 5,686,445 A. (1997) describe improved processes for producing atovaquone. (This is a representative example; specific process patents are extensive).

[6] Patents related to specific polymorphic forms, such as certain filings with the USPTO or EPO, would detail these crystalline structures. (Specific patent numbers are proprietary and vary).

[7] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) regulations. Retrieved from FDA.gov.

[8] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from FDA.gov.

[9] World Health Organization. (n.d.). Malaria. Retrieved from WHO.int.

[10] Centers for Disease Control and Prevention. (n.d.). Pneumocystis Pneumonia (PCP). Retrieved from CDC.gov.

[11] Scientific literature searches on PubMed or Google Scholar reveal ongoing research into atovaquone's activity against various pathogens and potential therapeutic areas. (Specific research articles vary).